Boswellia serrata resin — also known as Indian frankincense — is one of the more established botanical ingredients for joint-comfort products, with a resin extract that brands abroad specifically ask for by name. Its Japan status also has a detail worth knowing before you formulate: the plant genus and the resin are treated differently under Japanese law.
This guide is for brand owners planning a Boswellia product made in Japan. It covers what the trial evidence and a 2020 meta-analysis show, the specific Japan regulatory point that separates Boswellia from most other botanicals, how the ingredient is usually formulated, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a Boswellia product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
A 2020 meta-analysis of seven trials found Boswellia and its extract may relieve pain and stiffness and improve joint function compared with placebo, and individual short trials report improvements within days.
| Study | Design | Reported result |
|---|---|---|
| Systematic review and meta-analysis, BMC Complementary Medicine and Therapies 2020 (PMID 32680575) | 7 randomised controlled trials, 545 patients with joint pain, Boswellia or Boswellia extract vs control | Compared with control, Boswellia and its extract relieved pain and stiffness and improved function across VAS, WOMAC pain, WOMAC stiffness, WOMAC function and Lequesne index measures; the authors suggest at least 4 weeks of use to see an effect and reported no competing financial interests |
| Randomised, double-blind, placebo-controlled trial, Journal of the American Nutrition Association 2023 (PMID 35512759) | 70 adults with knee joint pain, 30 days, a standardised Boswellia serrata resin extract (100 mg/day) vs placebo | Significant improvements from day 5; by day 30, pain score down 45%, WOMAC pain down 44.4%, WOMAC stiffness down 66.3%, WOMAC function down 44.4% versus baseline, with reductions also seen in inflammatory markers; no significant adverse effects reported |
Caveats worth keeping in view:
- Trial size and duration. The individual trial above ran 30 days in 70 people; the meta-analysis pooled only seven trials and 545 patients in total. This is a small evidence base by supplement standards, and the meta-analysis authors called for larger studies.
- Population. Every trial in this evidence base recruited people with existing joint pain, not healthy people, and the research measures joint pain and stiffness outcomes in that population — a fact about the research, not a basis for product claims about treating a condition.
- Extract standardisation. Both sources studied a standardised extract of the resin, not raw Boswellia serrata gum in an unspecified form. Match your specification to a standardised extract if you want to rely on this evidence.
- Funding. Neither source available to us disclosed a funding statement; check the full-text funding declaration of any study before you cite it.
Checked against the published abstracts on 25 September 2026.
What Japanese products say
Japan draws a specific line inside the Boswellia genus: the whole plant is on the list of substances treated exclusively as medicines, except the resin of Boswellia serrata itself, which is explicitly excluded from that list.
The Ministry of Health, Labour and Welfare’s list of plant-derived substances used exclusively as pharmaceuticals covers the Boswellia genus as a whole, with a specific note excluding “the resin of Boswellia serrata” from that exclusively-medicinal classification. In practice, this means the resin extract — the part actually used in joint-comfort products — can be formulated as a food in Japan, while other parts or species of the same genus may not be. This is a narrower, more specific rule than for most botanicals, and it is worth confirming directly against the current MHLW list for your exact raw material (species, plant part and extraction method) before you commit to a formula.
💬 Need an evidence summary for your regulatory adviser that matches your exact extract and dose? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe Boswellia by what the trials measured in people with joint pain, not by a condition the product treats.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for joint comfort, stiffness and function” | Naming osteoarthritis or any joint disease as something the product treats |
| ”Contains a standardised Boswellia serrata resin extract, [X] mg per serving" | "Reduces inflammation” as a medical claim, or “works like a painkiller” |
| Naming the study and its population, with its limits | ”Clinically proven” without naming the study and its short duration |
How Boswellia is formulated
Boswellia resin extract is dosed in tens to low hundreds of milligrams, which is why capsules and tablets are the standard format.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Hard capsule | Matches the dose used in trials, masks the resin’s taste and smell | Extract standardisation and fill consistency |
| Tablet | Combines easily with other joint-comfort ingredients | Binder choice can affect disintegration of a resin-based extract |
Decisions that shape the specification:
- Species and plant part. Confirm the material is Boswellia serrata resin extract specifically, since Japan’s food/medicine line depends on that exact species and part.
- Standardisation. Ask the supplier for the extract’s standardisation (for example, its boswellic acid content) and match the daily amount to a study you intend to cite, such as the 100 mg/day used in the trial above.
- Companion ingredients. Boswellia is often combined with glucosamine, chondroitin or curcumin in joint-comfort formulas. Each companion needs its own check against Japanese food law.
- Documentation. Because the Japan rule turns on the specific plant part, keep the supplier’s species and part documentation on file for your Certificate of Free Sale application.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
For Boswellia specifically, that check has a sharp edge: the resin of Boswellia serrata is excluded from Japan’s exclusively-medicinal list, but the rest of the genus is not. Confirming the exact species, part and extraction method against the current MHLW list is the first step, before any other part of the formula. See the Japan-made supplement OEM page, and our glucosamine and chondroitin guides for other joint-comfort ingredients formulated the same way.
Before you ask for a quotation
A factory can quote accurately once the species, the extract standardisation, the daily amount and the companions are fixed.
- Confirmation that the material is Boswellia serrata resin extract, with supporting documentation
- Extract standardisation (for example, boswellic acid content) and daily amount
- Dosage form
- Companion ingredients and their amounts
- Packaging and target shelf life
- Countries you will sell in, and first order and annual volume
💬 Ready to design a Japan-made Boswellia product? Send us the concept — species confirmation, extract standardisation, daily amount and the countries you will sell in.
Frequently asked questions
1. Does Boswellia serrata help with joint pain?
A 2020 meta-analysis of seven trials in 545 patients with joint pain found Boswellia and its extract relieved pain and stiffness and improved function compared with placebo. The trials were relatively small and short, so describe it as studied for joint comfort and function rather than as a proven treatment.
2. How fast do effects show up in trials?
One 30-day trial of a standardised resin extract reported significant improvements from day 5, with pain and WOMAC scores down 44–66% by day 30 compared with baseline.
3. Is all Boswellia treated the same way under Japanese law?
No. The Boswellia genus as a whole is on Japan’s list of substances treated exclusively as medicines, but the resin of Boswellia serrata specifically is excluded from that list. Confirm your exact species, plant part and extraction method against the current list before formulating.
4. What dose does the trial evidence support?
One trial used 100 mg/day of a standardised resin extract for 30 days. Match your product’s daily amount to the standardisation and dose of the study you cite.
5. Can Boswellia be combined with other joint-comfort ingredients?
Yes, it is often paired with glucosamine, chondroitin or curcumin. Each companion ingredient needs its own check against Japanese food law before the formula is finalised.
Sources: “Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis”, BMC Complementary Medicine and Therapies 2020 (PMID 32680575); “Efficacy and Safety of a Novel Boswellia Serrata Extract in the Treatment of Osteoarthritis of the Knee: A Short-Term 30-Day Randomized, Double-Blind, Placebo-Controlled Clinical Study”, Journal of the American Nutrition Association 2023 (PMID 35512759); Ministry of Health, Labour and Welfare list of plant-derived substances used exclusively as pharmaceuticals (食薬区分における成分本質リスト), Boswellia genus entry noting exclusion of Boswellia serrata resin. Checked on 25 September 2026.